Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.84 |
| ▸ | PPARD | Q03181 | 5/20 | 0.84 |
| ▸ | PPARA | Q07869 | 5/20 | 0.84 |
| ▸ | F7 | P08709 | 5/20 | 0.84 |
| ▸ | F3 | P13726 | 5/20 | 0.84 |
| ▸ | TERT | O14746 | 3/20 | 0.84 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.84 |
| ▸ | FABP4 | P15090 | 3/20 | 0.84 |
| ▸ | TOP1 | P11387 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 2/20 | 0.84 |
| ▸ | BLM | P54132 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.84 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.84 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.84 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855222 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2573063 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2574228 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2858103 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2575442 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL17048016 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL4303654 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL808536 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL10201666 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 | |
| SCHEMBL2574226 | 1.00 | PPARG (0.84) | PPARGPPARDPPARAF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945651-B1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INST CANCER RES (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8334408-B2 | Analogs of alpha galactosylceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH | 2012-10-25 | — | — | US | disclosed |
| US-8188313-B2 | Analogs of alpha galactosylceramide and uses thereof | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | CERUNDOLO VINCENZO (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8039670-B2 | Analogs of alpha galactosyceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2009-09-24 | — | — | US | disclosed |
| EP-1945651-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | The Ludwig Institute for Cancer Research (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007050668-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | SGMS1, CERS2, SGMS2 | PPARG 4697/4885PPARD 3803/4885PPARA 4833/4885 |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, CD69, GALC | PPARG 1805/4885PPARD 2716/4885PPARA 2390/4885 |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, GALC, CD69 | PPARG 1809/4885PPARD 2691/4885PPARA 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.